Cara Therapeutics Inc (CARA)
0.7747
+0.04
(+4.90%)
USD |
NASDAQ |
May 02, 16:00
0.7747
0.00 (0.00%)
After-Hours: 16:40
Cara Therapeutics Enterprise Value: -60.39M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | -60.39M |
| April 30, 2024 | -59.66M |
| April 29, 2024 | -59.47M |
| April 26, 2024 | -63.36M |
| April 25, 2024 | -62.50M |
| April 24, 2024 | -64.05M |
| April 23, 2024 | -62.11M |
| April 22, 2024 | -60.84M |
| April 19, 2024 | -64.63M |
| April 18, 2024 | -63.05M |
| April 17, 2024 | -60.76M |
| April 16, 2024 | -62.01M |
| April 15, 2024 | -61.95M |
| April 12, 2024 | -59.00M |
| April 11, 2024 | -56.45M |
| April 10, 2024 | -56.38M |
| April 09, 2024 | -55.28M |
| April 08, 2024 | -55.64M |
| April 05, 2024 | -52.96M |
| April 04, 2024 | -55.62M |
| April 03, 2024 | -51.16M |
| April 02, 2024 | -50.50M |
| April 01, 2024 | -51.02M |
| March 28, 2024 | -51.02M |
| March 27, 2024 | -53.26M |
| Date | Value |
|---|---|
| March 26, 2024 | -60.85M |
| March 25, 2024 | -55.95M |
| March 22, 2024 | -52.48M |
| March 21, 2024 | -52.03M |
| March 20, 2024 | -51.41M |
| March 19, 2024 | -52.11M |
| March 18, 2024 | -51.16M |
| March 15, 2024 | -52.76M |
| March 14, 2024 | -57.77M |
| March 13, 2024 | -53.20M |
| March 12, 2024 | -52.66M |
| March 11, 2024 | -48.84M |
| March 08, 2024 | -47.12M |
| March 07, 2024 | -43.37M |
| March 06, 2024 | -46.64M |
| March 05, 2024 | -51.02M |
| March 04, 2024 | -46.11M |
| March 01, 2024 | -48.83M |
| February 29, 2024 | -54.44M |
| February 28, 2024 | -52.27M |
| February 27, 2024 | -49.25M |
| February 26, 2024 | -57.11M |
| February 23, 2024 | -51.34M |
| February 22, 2024 | -57.24M |
| February 21, 2024 | -63.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-72.42M
Minimum
Feb 08 2024
1.289B
Maximum
Apr 09 2021
452.22M
Average
497.11M
Median
May 19 2021
Enterprise Value Benchmarks
| Nektar Therapeutics | -0.6466M |
| Stereotaxis Inc | 183.69M |
| Cerus Corp | 326.54M |
| Avid Bioservices Inc | 596.33M |
| Rigel Pharmaceuticals Inc | 193.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.34M |
| Revenue (Quarterly) | 3.004M |
| Total Expenses (Quarterly) | 35.61M |
| EPS Diluted (Quarterly) | -0.60 |
| Gross Profit Margin (Quarterly) | 79.76% |
| Profit Margin (Quarterly) | -1.08K% |
| Earnings Yield | -282.7% |
| Normalized Earnings Yield | -282.69 |